Status:
COMPLETED
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
Lead Sponsor:
Novartis
Conditions:
Pre-diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated lev...
Eligibility Criteria
Inclusion
- BMI in the range 22-45 and with a stable weight for the last 6 months
- Blood glucose criteria must be met
- Written informed consent
Exclusion
- Pregnancy or lactation
- Previous diagnosis of type 2 diabetes or treatment with hypoglycemic agents
- Type 1 diabetes
- Evidence of cardiovascular complications as defined by the protocol
- Evidence of diabetic complications as defined by the protocol
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00312130
Start Date
April 1 2005
End Date
November 1 2006
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98108